TQ-B3101

DRUG4 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Advanced CancerAdvanced Malignant TumorPharmacokinetic StudyROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Phase 1

A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Cancer

Start: 2017-07-05End: 2018-12-31Target: 20Updated: 2017-09-18

A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects

CompletedNCT04804904

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Pharmacokinetic Study

Start: 2021-05-20End: 2021-07-03Updated: 2022-01-21

Phase 2

Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Start: 2019-07-24End: 2021-03-31Target: 111Updated: 2019-08-15

A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Malignant Tumor

Start: 2020-08-05End: 2021-09-30Target: 200Updated: 2020-08-18

Related Papers

Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial.

2023-06-3013 citations

A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101.

Journal of Clinical Oncology2020-05-209 citations